C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors

2024-517988-23-00 Protocol C6081001 Human pharmacology (Phase I) - First administration to humans Ended

End 12 May 2026 · Status Ended · 2 EU/EEA countries · 4 sites · Protocol C6081001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 230
Countries 2
Sites 4

KRAS mutated advanced solid tumors

Key facts

Sponsor
Pfizer Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
completed 12 May 2026
Decision date (initial)
2025-06-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

KRAS mutated advanced solid tumors

VersionLevelCodeTermSystem organ class
21.0 PT 10061451 Colorectal cancer 100000004864
20.0 PT 10073364 Ductal adenocarcinoma of pancreas 100000004864
27.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation
Pfizer Inc.
Address
66 Hudson Boulevard East
City
New York
Postcode
10001-2189
Country
United States

Scientific contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Locations

2 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 44 2
Spain Ended 17 2
Rest of world
United States, China, Japan
169

Investigational sites

France

2 sites · Ended
Institut Gustave Roussy
Département d'innovation Thérapeutique et des Essais Précoces (DITEP), 114 Rue Edouard Vaillant, 94800, Villejuif
Institut Curie
Pneumology, 26 Rue D Ulm, 75005, Paris

Spain

2 sites · Ended
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid
Institut Catala D'oncologia
Edificio de Consultas Externas, 2ª planta, Servicio de Oncología Médica, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-26 France Acceptable with conditions
2025-06-17
2025-06-19